Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Ann Transl Med ; 9(1): 44, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-1070024


BACKGROUND: The coronavirus disease 2019 (COVID-19) is spreading rapidly across countries and has infected tens of millions of people all over the world. So far, the pandemic is ongoing globally, and the situation is still worsening. METHODS: In this retrospective, single-center cohort analysis, we included 25 adult inpatients with laboratory confirmed COVID-19 disease from the affiliated hospital of Xuzhou Medical University (Xuzhou, China). Epidemiological characterizations, clinical findings, and medical treatments were all reported. In addition, laboratory markers were investigated in terms of course of treatment. RESULTS: Epidemiological features and clinical findings were present for all 25 patients. Laboratory markers were identified due to temporal changes. After medical treatment, all patients were discharged home and recovering from the infection. CONCLUSIONS: This study provides a comprehensive overview of patients with COVID-19 disease in a single hospital. Some of the laboratory markers were statistically different during the course of the disease, which might serve as indicators in identifying patients with COVID-19 disease at an early stage of the infection.

J Infect Dev Ctries ; 14(10): 1138-1145, 2020 Oct 31.
Article in English | MEDLINE | ID: covidwho-918914


INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading to more than 300,000 deaths up to 29 April 2020. Here, we present a critically ill case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs). CASE PRESENTATION: A 72-year-old man was admitted, with the diagnosis of COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, and hypertension. His clinical condition continually developed to be life-threatening even receiving various treatment options including antiviral therapy and extracorporeal membrane oxygenation. Between 28 February and 8 March 2020, the patient was given 5-time intravenous infusions of UCB-MSCs. His hematological and biochemical indexes, including lymphocytes and renal function improved. Pulmonary static compliance increased significantly and PaO2/FiO2 ratio maintained stable. On March 10, he received lung transplantation. CONCLUSIONS: Our current findings suggested that UCB-MSCs therapy may show some positive effect in treating critical COVID-19 to some extent, for its delaying deterioration of the disease and efficacy in respiratory and renal function, though limited.

Coronavirus Infections/therapy , Fetal Blood/cytology , Mesenchymal Stem Cell Transplantation , Pneumonia, Viral/therapy , Aged , Betacoronavirus , COVID-19 , Critical Illness , Fatal Outcome , Humans , Lung Transplantation , Male , Pandemics , SARS-CoV-2
Emerg Infect Dis ; 26(7): 1626-1628, 2020 07.
Article in English | MEDLINE | ID: covidwho-23371


We report epidemiologic, laboratory, and clinical findings for 7 patients with 2019 novel coronavirus disease in a 2-family cluster. Our study confirms asymptomatic and human-to-human transmission through close contacts in familial and hospital settings. These findings might also serve as a practical reference for clinical diagnosis and medical treatment.

Asymptomatic Diseases , Betacoronavirus , Coronavirus Infections/transmission , Pneumonia, Viral/transmission , Adult , COVID-19 , Family , Female , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2